SynthesisBMC pregnancy and childbirth2013
Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review.
Synthesis in BMC pregnancy and childbirth, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05789381 (Patient Satisfaction and Abbreviated Postpartum Magnesium Sulfate for Preeclampsia With Severe Features), which is not on this map. Cited by 27 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Patient Satisfaction and Abbreviated Postpartum Magnesium Sulfate for Preeclampsia With Severe Features: a Randomized Controlled Trial
Who cites it
27 citing papers in PubMed, 7 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2026Pooled it
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2024Pooled it
- Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis.PLoS medicine · 2019Pooled it
- Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.PLoS medicine · 2017Pooled it
- Clinical trials registries are underused in the pregnancy and childbirth literature: a systematic review of the top 20 journals.BMC research notes · 2016Pooled it
- Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour.The Cochrane database of systematic reviews · 2015Pooled it
- Creatine for women in pregnancy for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2014Pooled it
- A randomized controlled trial of loading dose alone versus pritchard regimen of magnesium sulphate, for seizure prophylaxis in severe preeclampsia.Annals of African medicineTrial
- Antenatal magnesium sulphate for preterm foetal neuroprotection in low- and middle-income countries: a scoping review of research studies and guidelines.Journal of global health · 2026Article
- The Molecular and Cellular Basis of Physiological Changes in Pregnancy and Its Implications in Neurologic and Ophthalmic Pathologies.International journal of molecular sciences · 2025Review
- Magnesium sulfate in oxidative stress-associated pathologies: clinical, cellular, and molecular perspectives.Biophysical reviews · 2025Review
- Effect of low-molecular-weight heparin calcium combined with magnesium sulfate and labetalol on coagulation, vascular endothelial function and pregnancy outcome in early-onset severe preeclampsia.European journal of clinical pharmacology · 2024Article
- Diagnosis and Treatment of Eclampsia.Journal of cardiovascular development and disease · 2024Review
- Article
- Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Health Care Readiness in Management of Preeclampsia/Eclampsia in Ethiopia: Evidence from National Facility-Based Survey.Risk management and healthcare policy · 2022Article
- Severe and critical COVID-19 in pregnancy: A case series from Montreal.Obstetric medicine · 2021Article
- Pregnancy and COVID-19: pharmacologic considerations.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2021Review
- Effect of magnesium sulfate combined with labetalol on serum sFlt-1/PlGF ratio in patients with early-onset severe pre-eclampsia.Experimental and therapeutic medicine · 2020Article
- Diagnosis and principles of management of gestational diabetes mellitus in the prevailing COVID-19 pandemic.International journal of diabetes in developing countries · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntenatal magnesium sulphate, widely used in obstetrics to improve maternal and infant outcomes, may be associated with adverse effects for the mother sufficient for treatment cessation. This systematic review aimed to quantify maternal adverse effects attributed to treatment, assess how adverse effects vary according to different regimens, and explore women's experiences with this treatment.
methodsBibliographic databases were searched from their inceptions to July 2012 for studies of any design that reported on maternal adverse effects associated with antenatal magnesium sulphate given to improve maternal or infant outcomes. Primary outcomes were life-threatening adverse effects of treatment (death, cardiac arrest, respiratory arrest). For randomised controlled trials, data were meta-analysed, and risk ratios (RR) pooled using fixed-effects or random-effects models. For non-randomised studies, data were tabulated by design, and presented as RR, odds ratios or percentages, and summarised narratively.
resultsA total of 143 publications were included (21 randomised trials, 15 non-randomised comparative studies, 32 case series and 75 reports of individual cases), of mixed methodological quality. Compared with placebo or no treatment, magnesium sulphate was not associated with an increased risk of maternal death, cardiac arrest or respiratory arrest. Magnesium sulphate significantly increased the risk of 'any adverse effects' overall (RR 4.62, 95% CI 2.42-8.83; 4 trials, 13,322 women), and treatment cessation due to adverse effects (RR 2.77; 95% CI 2.32-3.30; 5 trials, 13,666 women). Few subgroup differences were observed (between indications for use and treatment regimens). In one trial, a lower dose regimen (2 g/3 hours) compared with a higher dose regimen (5 g/4 hours) significantly reduced treatment cessation (RR 0.05; 95% CI 0.01-0.39, 126 women). Adverse effect estimates from studies of other designs largely supported data from randomised trials. Case reports supported an association between iatrogenic overdose of magnesium sulphate and life-threatening consequences.
conclusionsAppropriate administration of antenatal magnesium sulphate was not shown to be associated with serious maternal adverse effects, though an increase in 'minor' adverse effects and treatment cessation was shown. Larger trials are needed to determine optimal regimens, achieving maximal effectiveness with minimal adverse effects, for each antenatal indication for use. Vigilance in the use of magnesium sulphate is essential for women's safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.